---
title: Genitourinary Pathology
order: 5
category: Systemic Pathology
status: complete
last_updated: '2025-01-09'
---

# Genitourinary Pathology

## Overview

Genitourinary pathology encompasses diseases of the kidneys, ureters, bladder, urethra, male reproductive system, and female reproductive system. These disorders range from inflammatory and infectious conditions to neoplastic processes and represent major causes of morbidity and mortality worldwide.

### Epidemiology
- **Chronic kidney disease**: Affects 10-15% of population, leading cause of ESRD
- **Prostate cancer**: Most common cancer in men (excluding skin cancer)
- **Breast cancer**: Most common cancer in women
- **Cervical cancer**: Major preventable cancer (HPV vaccination, screening)
- **Ovarian cancer**: High mortality due to late detection

## Renal Pathology

### Glomerular Diseases

#### Overview
Glomerular diseases can present as:
- **Nephrotic syndrome**: Heavy proteinuria (>3.5 g/day), hypoalbuminemia, edema, hyperlipidemia
- **Nephritic syndrome**: Hematuria, oliguria, azotemia, hypertension, mild-moderate proteinuria
- **Rapidly progressive glomerulonephritis** (RPGN): Rapid decline in renal function over weeks
- **Asymptomatic hematuria/proteinuria**
- **Chronic kidney disease**

#### Minimal Change Disease (MCD)

**Most common cause of nephrotic syndrome in children** (90%)

**Epidemiology**:
- Peak age: 2-6 years
- Adults: 10-15% of nephrotic syndrome
- Excellent prognosis

**Pathogenesis**:
- T-cell dysfunction → circulating permeability factor
- Podocyte foot process effacement
- Loss of glomerular charge barrier
- Selective proteinuria (albumin)

**Associations**:
- Hodgkin lymphoma
- NSAIDs
- Atopy

**Pathology**:

**Light microscopy**: **Normal glomeruli** (hence "minimal change")

**Immunofluorescence**: Negative (no immune deposits)

**Electron microscopy**:
- **Diffuse podocyte foot process effacement** (hallmark)
- No immune complex deposits
- Normal basement membrane

**Clinical**:
- Sudden onset of edema
- Massive proteinuria (selective)
- Normal renal function
- Normal blood pressure

**Treatment**: **Steroids** (90% respond)

**Prognosis**: Excellent, usually no progression to ESRD

#### Focal Segmental Glomerulosclerosis (FSGS)

**Most common cause of nephrotic syndrome in adults** (especially African Americans)

**Epidemiology**:
- Increasing incidence
- African Americans at higher risk (APOL1 risk variants)
- Adults > children

**Classification**:
- **Primary (idiopathic)**: Unknown etiology
- **Secondary**:
  - HIV infection (collapsing variant)
  - Heroin use
  - Obesity (perihilar variant)
  - Sickle cell disease
  - Reflux nephropathy
- **Genetic**: NPHS1, NPHS2, INF2, TRPC6, APOL1 mutations

**Pathology**:

**Light microscopy**:
- **Segmental** (part of glomerular tuft) sclerosis in **some (focal)** glomeruli
- Sclerosis: Increased mesangial matrix, capillary collapse
- Hyalinosis: Protein deposits
- Podocyte hypertrophy/hyperplasia
- **Variants**: Tip lesion, cellular, collapsing, perihilar

**Immunofluorescence**:
- IgM and C3 in sclerotic segments (nonspecific trapping)

**Electron microscopy**:
- Foot process effacement (extensive, including non-sclerotic glomeruli)
- No immune deposits

**Clinical**:
- Nephrotic syndrome
- Hypertension common
- Hematuria
- Reduced renal function (in some)

**Treatment**:
- Steroids (less responsive than MCD, 30-40% respond)
- Immunosuppressants

**Prognosis**:
- 50% progress to ESRD within 10 years
- Recurrence in transplant (30-40%)
- Collapsing variant: Worst prognosis

#### Membranous Nephropathy (MN)

**Most common cause of primary nephrotic syndrome in Caucasian adults**

**Epidemiology**:
- Peak age: 40-60 years
- Men > women (2:1)

**Classification**:
- **Primary (75%)**: Autoantibodies against **PLA2R** (70%) or THSD7A (3%)
- **Secondary (25%)**:
  - Systemic lupus erythematosus (SLE)
  - Hepatitis B or C
  - Malignancy (solid tumors)
  - Drugs (NSAIDs, gold, penicillamine)

**Pathogenesis**:
- Antibodies against podocyte antigens (PLA2R)
- In situ immune complex formation
- Subepithelial deposits
- Complement activation (C5b-9)
- Podocyte injury

**Pathology**:

**Light microscopy**:
- Thickened glomerular basement membrane (GBM)
- **Spike and dome** pattern (silver stain): GBM projections between deposits
- Normal cellularity

**Immunofluorescence**:
- **Granular** deposits of **IgG and C3** along capillary walls

**Electron microscopy**:
- **Subepithelial electron-dense deposits** (hallmark)
- Basement membrane spikes between deposits
- Foot process effacement

**Staging**: I-IV based on deposit size and GBM changes

**Clinical**:
- Nephrotic syndrome (proteinuria, edema)
- Increased thrombotic risk (renal vein thrombosis)
- Gradual onset

**Treatment**:
- Spontaneous remission in 30%
- Immunosuppression (cyclophosphamide, rituximab)

**Prognosis**:
- Variable: 30% remit, 30% stable, 40% progress to ESRD

#### Poststreptococcal Glomerulonephritis (PSGN)

**Classic example of acute proliferative glomerulonephritis**

**Epidemiology**:
- Most common in children (2-14 years)
- Follows streptococcal infection (pharyngitis or skin)
- Latent period: 1-2 weeks (pharyngitis), 3-6 weeks (skin)

**Pathogenesis**:
- **Type III hypersensitivity** (immune complex)
- Antibodies to streptococcal antigens
- Immune complex deposition in glomeruli
- Complement activation
- Inflammation

**Pathology**:

**Light microscopy**:
- **Diffuse proliferative glomerulonephritis**
- Hypercellular glomeruli (mesangial and endothelial proliferation)
- Neutrophil infiltration
- **"Starry sky"** pattern

**Immunofluorescence**:
- **Granular** (lumpy-bumpy) deposits of **IgG and C3** along capillary walls and mesangium

**Electron microscopy**:
- **Subepithelial deposits** ("humps")
- Mesangial and subendothelial deposits

**Clinical**:
- **Nephritic syndrome**:
  - Hematuria (tea/cola-colored urine)
  - Proteinuria (mild-moderate)
  - Oliguria
  - Hypertension
  - Periorbital edema
- Preceding streptococcal infection
- Low C3 (consumed)
- Elevated ASO titers

**Treatment**: Supportive (diuretics, antihypertensives)

**Prognosis**:
- **Excellent in children**: 95% full recovery
- Adults: Higher risk of progression

#### Rapidly Progressive Glomerulonephritis (RPGN)

**Definition**: Acute nephritis with rapid loss of renal function (days to weeks), often with crescents

**Crescents**: Proliferation of parietal epithelial cells and macrophages in Bowman's space

**Classification by immunofluorescence**:

**Type I: Anti-GBM disease** (Goodpasture syndrome):
- Autoantibodies against collagen IV α3 chain (NC1 domain)
- **Linear IgG** along GBM
- Kidney and lung involvement (pulmonary hemorrhage)
- Young men
- HLA-DR2 association
- Treatment: Plasmapheresis, immunosuppression
- Poor prognosis without treatment

**Type II: Immune complex-mediated**:
- Postinfectious GN
- Lupus nephritis
- IgA nephropathy (Henoch-Schönlein purpura)
- **Granular** immunofluorescence
- Treat underlying disease

**Type III: Pauci-immune (ANCA-associated)**:
- Microscopic polyangiitis
- Granulomatosis with polyangiitis (Wegener's)
- **Negative or minimal immunofluorescence** (pauci-immune)
- **ANCA positive** (c-ANCA/PR3 or p-ANCA/MPO)
- Necrotizing vasculitis
- Treatment: Cyclophosphamide, rituximab
- Can recur

**Pathology** (all types):
- **Crescents** (>50% of glomeruli for RPGN diagnosis)
- Cellular (early), fibrocellular, fibrous (late)
- Glomerular necrosis
- Disruption of Bowman's capsule (fibrin in Bowman's space)

**Clinical**: Rapidly declining GFN, oliguria, hematuria, proteinuria

#### IgA Nephropathy (Berger Disease)

**Most common glomerulonephritis worldwide**

**Epidemiology**:
- Asians and Caucasians > African Americans
- Men > women (2:1)
- Peak age: 20-30 years

**Pathogenesis**:
- Abnormal galactosylation of IgA1
- Formation of IgA1-containing immune complexes
- Mesangial deposition
- Complement activation (alternative pathway)
- Inflammation and proliferation

**Associations**:
- Upper respiratory infection (often precedes hematuria by 1-2 days)
- Liver disease (cirrhosis)
- Celiac disease

**Pathology**:

**Light microscopy**:
- **Mesangial proliferation** and matrix expansion
- Variable severity (minimal to crescentic GN)

**Immunofluorescence**:
- **Dominant or codominant IgA** in mesangium (diagnostic)
- C3, IgG, IgM may be present

**Electron microscopy**:
- Mesangial electron-dense deposits

**Clinical**:
- **Episodic gross hematuria** with URI (synpharyngitic, unlike PSGN which has latent period)
- Persistent microscopic hematuria between episodes
- Proteinuria (variable)
- Normal complement levels
- Elevated serum IgA (50%)

**Prognosis**:
- Variable
- 25-50% progress to ESRD over 20 years
- Poor prognostic factors: Proteinuria, hypertension, reduced GFR, crescents
- Recurs in transplant

**Henoch-Schönlein Purpura (IgA Vasculitis)**:
- Systemic variant of IgA nephropathy
- Children (peak 4-6 years)
- Triad: Palpable purpura, arthritis, abdominal pain
- Glomerulonephritis (IgA deposition, identical to IgA nephropathy)

#### Diabetic Nephropathy

**Leading cause of end-stage renal disease** (40% of ESRD cases)

**Epidemiology**:
- Type 1 DM: 30-40% develop nephropathy
- Type 2 DM: 20-30% develop nephropathy
- African Americans, Native Americans at higher risk

**Pathogenesis**:
- **Chronic hyperglycemia**:
  - Advanced glycation end products (AGEs)
  - Increased polyol pathway
  - Oxidative stress
  - Activation of PKC
- **Hemodynamic changes**:
  - Glomerular hyperfiltration (efferent arteriole vasoconstriction from angiotensin II)
  - Increased intraglomerular pressure
  - Glomerular hypertrophy
- **Cytokines and growth factors**:
  - TGF-β: Promotes matrix production, fibrosis
  - VEGF: Increases permeability
- Result: Mesangial expansion, GBM thickening, sclerosis

**Pathology**:

**Glomerular lesions**:
- **GBM thickening** (earliest change)
- **Mesangial expansion**: Increased matrix
- **Kimmelstiel-Wilson nodules**: Nodular glomerulosclerosis (pathognomonic but not always present)
  - Acellular, PAS-positive nodules in mesangium
  - Peripheral nuclei
  - "Balls of yarn"
- **Diffuse glomerulosclerosis**: More common than nodular
- **Capsular drops**: Subendothelial hyaline deposits
- **Fibrin caps**: Fibrin on capillary loops

**Vascular lesions**:
- Hyaline arteriolosclerosis (afferent and efferent arterioles)
- Atherosclerosis (larger vessels)

**Tubulointerstitial**:
- **Armanni-Ebstein lesion**: Glycogen in tubular epithelium (poorly controlled DM)
- Tubular atrophy
- Interstitial fibrosis

**Clinical stages**:
1. **Hyperfiltration**: Increased GFR, glomerular hypertrophy (years 0-5)
2. **Normoalbuminuria**: GFR normalizes, GBM thickening (years 5-10)
3. **Microalbuminuria**: 30-300 mg/day (years 10-15)
4. **Overt proteinuria**: >300 mg/day, nephrotic syndrome (years 15-20)
5. **ESRD**: GFR <15 (years 20-25)

**Clinical features**:
- Proteinuria (initially microalbuminuria)
- Hypertension
- Progressive renal insufficiency
- Often have diabetic retinopathy (strong association)

**Treatment**:
- Glycemic control (HbA1c <7%)
- Blood pressure control (<130/80)
- **RAAS inhibition**: ACE inhibitors or ARBs (slow progression)
- SGLT2 inhibitors (cardioprotective and renoprotective)

**Prognosis**:
- Progression varies
- ACE inhibitors/ARBs delay but don't prevent ESRD
- Eventually require dialysis or transplant

### Acute Kidney Injury

#### Acute Tubular Necrosis (ATN)

**Most common cause of acute kidney injury** (hospital setting)

**Etiology**:

**Ischemic ATN** (most common, 50%):
- Hypotension, shock
- Cardiac arrest
- Major surgery
- Sepsis
- Severe volume depletion

**Nephrotoxic ATN**:
- **Drugs**: Aminoglycosides, cisplatin, amphotericin B, NSAIDs
- **Contrast agents**: Radiocontrast dyes
- **Pigments**: Myoglobin (rhabdomyolysis), hemoglobin (hemolysis)
- **Heavy metals**: Mercury, lead
- **Organic solvents**: Ethylene glycol

**Pathogenesis**:
- Tubular epithelial cell injury and death
- Loss of brush border
- Tubular obstruction (cellular debris, casts)
- Backleak of filtrate
- Reduced GFR
- Renal vasoconstriction

**Pathology**:

**Ischemic ATN**:
- **Proximal tubule** (straight segments) and **thick ascending limb** most vulnerable
- Loss of brush border
- Flattened epithelium
- Tubular dilation
- Casts in distal tubules
- **Patchy necrosis** (skip lesions)
- Interstitial edema
- Regenerating epithelium (mitoses, basophilic cytoplasm)

**Toxic ATN**:
- **More extensive, diffuse** necrosis
- Proximal tubule predominantly affected
- May see specific findings:
  - Myoglobin casts (reddish-brown, muddy brown)
  - Oxalate crystals (ethylene glycol)

**Clinical**:
- Abrupt decrease in urine output (oliguria or anuria)
- Azotemia (elevated BUN and creatinine)
- Hyperkalemia
- Metabolic acidosis
- Urinalysis: Muddy brown casts, renal tubular epithelial cells
- FENa >2% (intrinsic renal)

**Phases**:
1. **Initiation**: Injury occurs (hours to days)
2. **Maintenance**: Oliguria, azotemia (1-3 weeks)
3. **Recovery**: Polyuria (diuresis), improvement in renal function

**Treatment**:
- Supportive care
- Avoid nephrotoxins
- Maintain euvolemia
- Dialysis if severe (hyperkalemia, pulmonary edema, uremia)

**Prognosis**:
- **Reversible** if tubular basement membrane intact
- Mortality: 50% (often from underlying illness, not AKI itself)
- Incomplete recovery in some (CKD)

### Chronic Kidney Disease

#### Definition
Progressive irreversible loss of renal function over months to years.

#### Etiology (most common causes):
- **Diabetes mellitus** (40%)
- **Hypertension** (25-30%)
- **Glomerulonephritis** (10-15%)
- **Polycystic kidney disease**
- **Chronic pyelonephritis/reflux nephropathy**
- **Obstructive uropathy**

#### Pathophysiology
- Initial injury → nephron loss
- **Adaptive hyperfiltration** in remaining nephrons
- Glomerular hypertension and hypertrophy
- **Focal segmental glomerulosclerosis** develops
- Progressive injury to remaining nephrons
- **Vicious cycle** → ESRD

#### Pathology (End-stage kidney)
**Gross**:
- Small, shrunken kidneys (usually <100 g each)
- Thin cortex
- Granular surface
- Loss of corticomedullary junction

**Microscopic**:
- **Global glomerulosclerosis** (most glomeruli)
- Tubular atrophy
- Interstitial fibrosis
- Interstitial chronic inflammation
- Arterial and arteriolar sclerosis
- **Difficult to determine original disease**

**Clinical stages** (based on GFR):
- Stage 1: GFR >90 (kidney damage with normal GFR)
- Stage 2: GFR 60-89 (mild decrease)
- Stage 3: GFR 30-59 (moderate decrease)
- Stage 4: GFR 15-29 (severe decrease)
- Stage 5: GFR <15 (kidney failure, ESRD)

**Complications**:
- **Uremia**: Accumulation of nitrogenous wastes
  - Nausea, vomiting, anorexia
  - Encephalopathy
  - Pericarditis
  - Platelet dysfunction (bleeding)
- **Fluid and electrolyte imbalances**:
  - Volume overload
  - Hyperkalemia
  - Metabolic acidosis
  - Hypocalcemia, hyperphosphatemia
- **Anemia**: Decreased erythropoietin
- **Renal osteodystrophy**: Secondary hyperparathyroidism
- **Cardiovascular disease**: Leading cause of death

**Treatment**:
- Slow progression: BP control, RAAS inhibition, glycemic control
- Manage complications: Anemia (ESA), bone disease (phosphate binders, vitamin D), acidosis
- Renal replacement therapy: Dialysis or transplantation

### Renal Neoplasms

#### Renal Cell Carcinoma (RCC)

**Most common malignant tumor of the kidney in adults** (85-90%)

**Epidemiology**:
- Peak age: 60-70 years
- Men > women (2:1)
- Incidence increasing

**Risk factors**:
- Smoking (most important)
- Obesity
- Hypertension
- Acquired cystic kidney disease (dialysis patients)
- Von Hippel-Lindau (VHL) disease
- Tuberous sclerosis

**Classification** (WHO 2016):

**Clear Cell RCC** (70-80%):
- **VHL gene inactivation** (chromosome 3p deletion/mutation)
  - Sporadic (75%) or hereditary VHL syndrome (25%)
- **Pathology**:
  - Golden-yellow tumor (lipid, glycogen)
  - Nests and sheets of cells
  - **Clear cytoplasm** (lipid, glycogen)
  - Prominent vasculature ("chicken wire")
  - Nuclei: Variable grade (Fuhrman 1-4)
- **Immunohistochemistry**: Positive for RCC, CD10, carbonic anhydrase IX (CAIX)
- **Molecular**: VHL inactivation → HIF stabilization → VEGF, PDGF upregulation
- **Treatment**: Surgery, immunotherapy (anti-PD-1, anti-CTLA-4), TKIs (sunitinib, pazopanib)
- **Prognosis**: Depends on stage and grade

**Papillary RCC** (10-15%):
- **Genetics**: Trisomy 7, 17; loss of Y
  - Type 1: MET mutations
- **Pathology**:
  - Papillae with fibrovascular cores
  - **Type 1**: Small cells, basophilic cytoplasm, low grade
  - **Type 2**: Large cells, eosinophilic cytoplasm, high grade
  - Foamy macrophages, psammoma bodies
- **Prognosis**: Type 1 better than type 2

**Chromophobe RCC** (5%):
- **Genetics**: Multiple chromosome losses (heterozygous)
- **Pathology**:
  - Solid sheets
  - Pale, flocculent cytoplasm
  - Prominent cell membranes ("plant-like")
  - Perinuclear halos (koilocytosis-like)
- **Electron microscopy**: Numerous microvesicles
- **Prognosis**: Best of RCC subtypes

**Collecting Duct/Medullary Carcinoma** (<1%):
- Aggressive
- Medullary location
- Young patients
- Sickle cell trait (medullary subtype)
- Poor prognosis

**Gross pathology** (general):
- Upper pole or lower pole
- Yellow-tan (clear cell) or gray (others)
- Well-circumscribed but not encapsulated
- Hemorrhage, necrosis, cystic change
- May invade renal vein → IVC → right atrium

**Clinical features**:
- **Classic triad** (10%): Hematuria, flank pain, palpable mass
- Often asymptomatic (incidental finding on imaging)
- **Paraneoplastic syndromes** (30%):
  - Polycythemia (EPO production)
  - Hypercalcemia (PTHrP)
  - Hypertension (renin)
  - Hepatic dysfunction (Stauffer syndrome)
  - Fever, weight loss, anemia

**Staging**: TNM system

**Metastases**: Lung (most common), bone, liver, brain

**Prognosis**: Depends on stage, grade, subtype

#### Wilms Tumor (Nephroblastoma)

**Most common renal malignancy in children**

**Epidemiology**:
- Peak age: 2-5 years
- Unilateral (90%), bilateral (10%)

**Genetics**:
- **WT1** gene mutations (chromosome 11p13)
- **WT2** locus (11p15)
- WAGR syndrome: Wilms, Aniridia, Genitourinary anomalies, intellectual disability (Range)
- Denys-Drash syndrome: Wilms, nephropathy, male pseudohermaphroditism
- Beckwith-Wiedemann syndrome: Organomegaly, hemihypertrophy, omphalocele, increased tumor risk

**Pathology**:
- **Triphasic** (classic):
  1. **Blastemal**: Small blue cells
  2. **Stromal**: Spindle cells, cartilage, muscle, bone
  3. **Epithelial**: Tubules, glomeruloid structures
- May have one or two components
- Well-circumscribed, soft, tan-gray mass
- Pseudocapsule
- Necrosis, hemorrhage

**Favorable histology** (90%): Standard components, no anaplasia

**Unfavorable histology** (10%):
- **Anaplasia**: Markedly enlarged, hyperchromatic, multipolar mitoses
  - Focal or diffuse
  - Worse prognosis

**Clinical**:
- Abdominal mass (most common)
- Hypertension (renin)
- Hematuria
- Fever

**Treatment**: Surgery, chemotherapy, radiation (selected cases)

**Prognosis**:
- **Excellent with favorable histology**: >90% cure rate
- Unfavorable histology: 50-60% survival

## Urological Pathology

### Bladder Cancer (Urothelial Carcinoma)

#### Epidemiology
- 4th most common cancer in men
- Men > women (3:1)
- Peak age: 60-70 years

#### Risk Factors
- **Smoking**: Most important (50% of cases), 4× risk
- **Occupational exposures**: Aromatic amines (dye, rubber, textile industries)
- **Schistosomiasis**: Squamous cell carcinoma (endemic areas)
- **Cyclophosphamide**
- **Chronic cystitis**
- **Radiation**

#### Pathology

**Urothelial (Transitional Cell) Carcinoma** (90%):

**Gross**:
- **Papillary** (70%): Exophytic, finger-like projections
- **Flat/invasive** (30%): Ulcerated, infiltrative
- Location: Trigone, lateral walls

**Microscopic**:
- Papillae with fibrovascular cores
- Urothelial cells (7 layers normally)
- Atypia, increased mitoses
- **Grading**: Low-grade vs. High-grade (WHO 2016)
- **Staging**: Depth of invasion (lamina propria vs. muscularis propria)

**Non-invasive**:
- **Papillary urothelial neoplasm of low malignant potential (PUNLMP)**: Minimal atypia
- **Non-invasive low-grade papillary carcinoma**
- **Non-invasive high-grade papillary carcinoma**
- **Carcinoma in situ (CIS)**: Flat, high-grade, non-invasive
  - High risk for progression to invasive

**Invasive**: Invades lamina propria or deeper

**Staging** (TNM):
- **Ta**: Non-invasive papillary
- **Tis**: Carcinoma in situ
- **T1**: Lamina propria invasion
- **T2**: Muscularis propria invasion (muscle-invasive, requires cystectomy)
- **T3**: Perivesical tissue
- **T4**: Adjacent organs

**Squamous Cell Carcinoma** (5%):
- Schistosomiasis (Egypt, Middle East)
- Chronic irritation (stones, catheters)
- Keratinizing, invasive

**Adenocarcinoma** (1%):
- Urachal remnant
- Glandular differentiation
- Poor prognosis

**Clinical**:
- **Painless hematuria** (gross or microscopic) - hallmark
- Dysuria, frequency, urgency
- Hydronephrosis (ureteral obstruction)

**Diagnosis**: Cystoscopy with biopsy, urine cytology

**Treatment**:
- **Non-muscle-invasive**: Transurethral resection (TURBT), intravesical BCG or chemotherapy
- **Muscle-invasive**: Radical cystectomy ± neoadjuvant chemotherapy
- **Metastatic**: Chemotherapy (cisplatin-based), immunotherapy (anti-PD-1/PD-L1)

**Prognosis**:
- Non-invasive: 5-year survival >95%, but high recurrence (50-70%)
- Muscle-invasive: 5-year survival 50-60%
- Metastatic: 5-year survival <10%

## Male Reproductive Pathology

### Prostate Pathology

#### Benign Prostatic Hyperplasia (BPH)

**Extremely common in aging men**

**Epidemiology**:
- Microscopic: 50% at 50 years, 90% at 80 years
- Symptomatic: 50% of men >60 years

**Pathogenesis**:
- **Dihydrotestosterone (DHT)**: Testosterone converted by 5α-reductase
- DHT binds androgen receptors
- Stimulates growth of stromal and epithelial cells
- Estrogen may also play a role

**Pathology**:

**Gross**:
- **Nodular enlargement** of **transition zone** (periurethral)
  - Adenocarcinoma typically in peripheral zone
- Nodules compress urethra
- Can compress peripheral zone

**Microscopic**:
- **Glandular (epithelial) hyperplasia**: Increased number and size of glands
- **Stromal hyperplasia**: Smooth muscle and fibrous tissue
- Variable proportions (stromal-predominant or glandular-predominant)
- Glands: Two cell layers (basal and secretory), papillary infoldings
- Corpora amylacea (laminated concretions in glands)

**Clinical**:
- **Obstructive symptoms**:
  - Hesitancy
  - Weak stream
  - Incomplete emptying
  - Urinary retention
- **Irritative symptoms**:
  - Frequency
  - Urgency
  - Nocturia
- Complications: Hydronephrosis, UTIs, bladder stones, acute retention

**Diagnosis**:
- Digital rectal exam (DRE): Enlarged, smooth, firm
- PSA may be mildly elevated
- Urinalysis, uroflowmetry

**Treatment**:
- **α-blockers**: Tamsulosin (relax smooth muscle)
- **5α-reductase inhibitors**: Finasteride (shrink prostate)
- Surgery: TURP (transurethral resection of prostate) if severe

#### Prostatic Adenocarcinoma

**Most common cancer in men** (excluding skin cancer)

**Epidemiology**:
- 1 in 8 men develop prostate cancer
- 2nd leading cause of cancer death in men (after lung)
- Incidence increases with age (rare <50)
- African Americans: Higher incidence and mortality
- Family history increases risk

**Risk factors**:
- Age (most important)
- African American race
- Family history (BRCA2 mutations)
- Diet (high fat, low vegetables)

**Pathogenesis**:
- Multifactorial: Genetic, hormonal, environmental
- Androgen-dependent
- Molecular alterations:
  - TMPRSS2-ERG fusion (50%)
  - PTEN loss
  - MYC amplification
  - TP53, RB1 (advanced disease)

**Pathology**:

**Gross**:
- **Peripheral zone** (70%): Posterior, palpable on DRE
- Transition zone (20%): May be incidental in TURP
- Central zone (10%)
- Firm, yellow-white, irregular
- Infiltrative, ill-defined

**Microscopic**:
- **Adenocarcinoma**: Malignant glands
- **Loss of basal cell layer** (hallmark, differentiates from benign)
- Small, crowded, back-to-back glands
- Nuclear atypia (enlarged nucleoli)
- Infiltrative growth
- Perineural invasion common
- Collagenous micronodules (mucinous fibroplasia)

**Immunohistochemistry** (helpful in diagnosis):
- **Basal cell markers** (p63, high-molecular-weight cytokeratin): **Absent** in carcinoma
- **AMACR** (α-methylacyl-CoA racemase): **Positive** in carcinoma

**Gleason Grading System**:
- Based on architectural pattern (not cytology)
- Two most common patterns graded 1-5
- **Gleason score**: Primary + secondary (e.g., 3+4=7)
- **Grade groups** (2014):
  - Grade Group 1: Gleason ≤6 (3+3)
  - Grade Group 2: Gleason 7 (3+4)
  - Grade Group 3: Gleason 7 (4+3)
  - Grade Group 4: Gleason 8 (4+4, 3+5, 5+3)
  - Grade Group 5: Gleason 9-10 (4+5, 5+4, 5+5)
- Higher score → worse prognosis

**Patterns**:
- **Pattern 3**: Well-formed separate glands
- **Pattern 4**: Fused glands, cribriform, ill-defined
- **Pattern 5**: Sheets, single cells, comedonecrosis

**Staging**: TNM system
- **T1**: Non-palpable, incidental
- **T2**: Palpable, organ-confined
- **T3**: Extraprostatic extension
- **T4**: Invades adjacent structures (bladder, rectum)
- **N**: Lymph node metastases
- **M**: Distant metastases (bone most common)

**Clinical**:
- **Often asymptomatic** (early stage)
- Obstructive urinary symptoms (advanced)
- Bone pain (metastases)
- Elevated PSA (screening)
  - >4 ng/mL: Consider biopsy
  - PSA velocity, PSA density

**Diagnosis**:
- **DRE**: Irregular, hard nodule
- **PSA**: Elevated (not specific, also elevated in BPH, prostatitis)
- **Transrectal ultrasound-guided biopsy**: Definitive

**Metastases**:
- **Osteoblastic bone metastases** (characteristic): Lumbar spine, pelvis, femur
- Lymph nodes
- Lungs, liver

**Treatment**:
- **Localized disease**:
  - Active surveillance (low-grade)
  - Radical prostatectomy
  - Radiation therapy
- **Advanced/metastatic**:
  - Androgen deprivation therapy (ADT): LHRH agonists, antiandrogens
  - Chemotherapy (docetaxel, cabazitaxel)
  - Newer agents: Abiraterone, enzalutamide (AR pathway inhibitors)
  - Radium-223 (bone metastases)
  - Immunotherapy (sipuleucel-T)

**Prognosis**:
- **Localized disease**: Excellent (>95% 5-year survival)
- **Regional spread**: 85-90% 5-year survival
- **Distant metastases**: 30% 5-year survival
- Many prostate cancers are indolent (die with, not from)

### Testicular Tumors

#### Overview
**Most common solid malignancy in men aged 15-35 years**

**Classification**:
- **Germ cell tumors** (95%)
- **Sex cord-stromal tumors** (5%)

#### Germ Cell Tumors (GCT)

**Epidemiology**:
- Peak: 20-35 years
- Caucasians > African Americans
- Risk factors:
  - **Cryptorchidism** (undescended testis): 10× risk
  - Testicular dysgenesis
  - Klinefelter syndrome
  - Family history

**Pathogenesis**:
- **Germ cell neoplasia in situ (GCNIS)**: Precursor lesion
  - Large cells with clear cytoplasm
  - Central nuclei, prominent nucleoli
  - OCT4 positive (marker of pluripotency)
  - Progresses to invasive GCT in 5 years (50%)

**Classification**:

**Seminoma** (50%):
- **Pure population** of primitive germ cells
- **Gross**: Lobulated, tan-white, homogeneous, soft
- **Microscopic**:
  - Sheets of uniform cells
  - Large cells, clear cytoplasm ("fried egg")
  - Central nuclei, prominent nucleoli
  - Lymphocytic infiltrate (often with granulomas)
  - Fibrous septa
- **Immunohistochemistry**:
  - OCT4, PLAP, CD117 (c-KIT) positive
  - AFP negative (important: excludes yolk sac component)
- **Syncytiotrophoblast cells**: Scattered (10-15%), hCG production
- **Age**: 30-40 years (average)
- **Sensitive to radiation**
- **Prognosis**: Excellent (>95% cure rate)
- **Spreads via lymphatics**

**Embryonal Carcinoma** (35%, pure form rare):
- **Primitive, poorly differentiated**
- **Gross**: Variegated, hemorrhage, necrosis
- **Microscopic**:
  - Sheets, glands, papillae
  - Primitive epithelial cells
  - Large, pleomorphic nuclei
  - Prominent nucleoli
  - High mitotic rate, necrosis
- **Immunohistochemistry**: OCT4, CD30 positive; AFP, hCG negative (unless other components)
- **Aggressive**
- **Can differentiate** into other GCT types
- **Age**: 20-30 years

**Yolk Sac Tumor** (most common in children <3 years, component in adults):
- **Differentiation toward yolk sac**
- **Microscopic**:
  - **Schiller-Duval bodies**: Glomeruloid structures with central vessel (pathognomonic)
  - Microcystic, reticular, solid patterns
  - Hyaline globules (AFP-positive)
- **Immunohistochemistry**: AFP positive (elevated serum AFP)
- **Pure form in children**: Excellent prognosis
- **Component in adults**: Worse prognosis

**Choriocarcinoma** (rare as pure form, 1%):
- **Differentiation toward placenta**
- **Microscopic**:
  - **Biphasic**: Cytotrophoblasts and syncytiotrophoblasts
  - Hemorrhage, necrosis
- **Immunohistochemistry**: hCG positive (very high levels)
- **Highly aggressive**: Early hematogenous spread (lungs, brain, liver)
- **Prognosis**: Poor if pure

**Teratoma**:
- **Differentiation toward somatic tissues** (all 3 germ layers)
- **Prepubertal**: Benign (pure teratoma)
- **Postpubertal**: Malignant potential (component of mixed GCT)
- **Microscopic**: Cartilage, bone, muscle, glands, neural tissue, etc.
- **Mature**: Well-differentiated tissues
- **Immature**: Primitive tissues
- **Chemoresistant**: May grow during chemotherapy (growing teratoma syndrome)

**Mixed Germ Cell Tumor** (40%):
- Most common type overall
- Combination of above types
- Most common: Embryonal carcinoma + teratoma; embryonal carcinoma + yolk sac + teratoma

**Clinical**:
- **Painless testicular mass** (most common)
- Testicular enlargement, heaviness
- Gynecomastia (hCG production)
- Abdominal/back pain (retroperitoneal metastases)

**Tumor markers**:
- **AFP**: Yolk sac tumor, embryonal carcinoma (component)
- **hCG**: Choriocarcinoma, syncytiotrophoblasts in seminoma
- **LDH**: Non-specific, correlates with tumor burden

**Staging**:
- **Stage I**: Testis only
- **Stage II**: Retroperitoneal lymph nodes
- **Stage III**: Distant metastases (supradiaphragmatic nodes, visceral)

**Treatment**:
- **Radical inguinal orchiectomy** (primary treatment)
- **Surveillance** (stage I, low-risk)
- **Radiation** (seminoma, stage I-II)
- **Chemotherapy** (non-seminomatous, advanced): BEP (bleomycin, etoposide, cisplatin)
- **Retroperitoneal lymph node dissection** (RPLND) for residual masses

**Prognosis**:
- **Overall cure rate >95%** (even with metastases)
- **Seminoma**: Excellent
- **Non-seminomatous GCT**: Very good with chemotherapy

## Female Reproductive Pathology

### Cervical Pathology

#### Cervical Intraepithelial Neoplasia (CIN) and Cervical Cancer

**Human Papillomavirus (HPV)** is the causative agent

**Epidemiology**:
- Most common sexually transmitted infection
- >80% of sexually active individuals infected at some point
- Most infections clear spontaneously (90% within 2 years)
- Persistent infection → dysplasia → cancer

**HPV types**:
- **High-risk** (oncogenic): 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
  - **HPV 16**: 50% of cervical cancers
  - **HPV 18**: 20% of cervical cancers
- **Low-risk**: 6, 11 (condyloma, low-grade lesions, not cancer)

**Pathogenesis**:
- HPV infects basal cells (transformation zone)
- **E6 and E7 oncoproteins**:
  - **E6** inactivates **p53** (apoptosis inhibition)
  - **E7** inactivates **RB** (cell cycle dysregulation)
- Genomic instability
- Dysplasia → carcinoma in situ → invasive carcinoma

**Pathology**:

**CIN grading** (historical):
- **CIN 1**: Lower 1/3 of epithelium (mild dysplasia)
- **CIN 2**: Lower 2/3 of epithelium (moderate dysplasia)
- **CIN 3**: Full thickness (severe dysplasia, carcinoma in situ)

**Bethesda System** (current, cytology):
- **LSIL** (Low-grade squamous intraepithelial lesion): CIN 1, HPV changes
  - Koilocytosis: Perinuclear halo, wrinkled nuclei (HPV cytopathic effect)
- **HSIL** (High-grade squamous intraepithelial lesion): CIN 2-3
  - Crowded, hyperchromatic nuclei
  - High nuclear:cytoplasmic ratio
  - Loss of maturation

**Invasive Squamous Cell Carcinoma** (70% of cervical cancers):
- Breaches basement membrane
- Invades stroma
- Keratinizing, non-keratinizing, basaloid subtypes

**Adenocarcinoma** (25%):
- Endocervical glands
- HPV 18 association (higher)
- Poorer prognosis than squamous

**Screening**:
- **Pap smear** (cytology): Every 3 years (ages 21-65)
- **HPV co-testing**: Pap + HPV (ages 30-65, every 5 years)
- **HPV primary**: HPV test alone (ages 25-65, every 5 years)

**Clinical**:
- **Precancerous**: Asymptomatic (detected by screening)
- **Invasive**: Vaginal bleeding (postcoital, intermenstrual), discharge, pain

**Staging**: FIGO system
- **Stage I**: Confined to cervix
- **Stage II**: Beyond cervix but not to pelvic wall or lower 1/3 vagina
- **Stage III**: Extends to pelvic wall or lower 1/3 vagina
- **Stage IV**: Bladder, rectum, or distant metastases

**Treatment**:
- **LSIL**: Observation (often regresses)
- **HSIL**: Excision (LEEP, cone biopsy) or ablation
- **Invasive**: Surgery (hysterectomy ± lymphadenectomy), radiation, chemotherapy

**Prevention**:
- **HPV vaccine**: Gardasil-9 (9-valent, covers types 6, 11, 16, 18, 31, 33, 45, 52, 58)
  - Recommended ages 11-12, catch-up to age 26
  - 90% reduction in cervical precancers

**Prognosis**:
- **Localized**: 92% 5-year survival
- **Regional**: 56%
- **Distant**: 17%

### Endometrial Pathology

#### Endometrial Hyperplasia and Carcinoma

**Endometrial Hyperplasia**:
- Abnormal proliferation of endometrial glands
- **Estrogen stimulation** (unopposed)

**Classification** (WHO 2014):
- **Hyperplasia without atypia**: Low cancer risk (<5%)
- **Atypical hyperplasia (endometrioid intraepithelial neoplasia)**: High cancer risk (30-40%)

**Risk factors** (for hyperplasia and cancer):
- **Unopposed estrogen**:
  - Obesity (peripheral conversion of androgens to estrogens)
  - Exogenous estrogen (without progesterone)
  - Estrogen-producing tumors (granulosa cell)
  - Polycystic ovary syndrome (PCOS)
  - Early menarche, late menopause, nulliparity
- **Tamoxifen**: Partial agonist in endometrium
- **Lynch syndrome**: Hereditary
- **Diabetes, hypertension**

**Endometrial Carcinoma**:

**Epidemiology**:
- Most common gynecologic malignancy in developed countries
- Postmenopausal women (peak 60-70 years)

**Dualistic model**:

**Type I (80%)** - Estrogen-dependent:
- **Endometrioid adenocarcinoma**
- Precursor: Atypical hyperplasia
- Risk factors: Unopposed estrogen (obesity, PCOS, tamoxifen)
- Younger, obese, better prognosis
- **Molecular**: PTEN, PIK3CA, CTNNB1 mutations; microsatellite instability
- Well to moderately differentiated

**Type II (20%)** - Estrogen-independent:
- **Serous carcinoma**, clear cell carcinoma
- No precursor lesion
- Atrophic endometrium
- Older, thin women, worse prognosis
- **Molecular**: TP53 mutations (90% of serous)
- Poorly differentiated, aggressive

**Pathology**:

**Endometrioid Adenocarcinoma**:
- Glands resembling normal endometrium
- Back-to-back glands (no intervening stroma)
- Squamous differentiation common
- **Grading** (FIGO):
  - Grade 1: ≤5% solid growth
  - Grade 2: 6-50% solid growth
  - Grade 3: >50% solid growth

**Serous Carcinoma**:
- Papillae with psammoma bodies
- Marked nuclear atypia
- High grade by definition
- Spreads intraperitoneally (like ovarian)

**Staging**: FIGO (surgical)
- **Stage I**: Confined to uterus
- **Stage II**: Cervical involvement
- **Stage III**: Local/regional spread
- **Stage IV**: Bladder, bowel, distant metastases

**Clinical**:
- **Postmenopausal bleeding** (most common presentation)
- Abnormal uterine bleeding (premenopausal)
- Diagnosis: **Endometrial biopsy** or D&C

**Treatment**:
- **Surgery**: Total hysterectomy with bilateral salpingo-oophorectomy ± lymphadenectomy
- **Radiation**: Adjuvant
- **Chemotherapy/hormonal**: Advanced disease

**Prognosis**:
- Type I (endometrioid): 85% 5-year survival
- Type II (serous): 50% 5-year survival

### Ovarian Pathology

#### Ovarian Tumors

**Classification** (by cell of origin):

**Surface Epithelial Tumors** (65-70%):
- Serous, mucinous, endometrioid, clear cell, Brenner
- Can be benign, borderline (low malignant potential), or malignant

**Germ Cell Tumors** (15-20%):
- Teratoma, dysgerminoma, yolk sac, choriocarcinoma

**Sex Cord-Stromal Tumors** (5-10%):
- Granulosa cell, thecoma, fibroma, Sertoli-Leydig

#### Serous Tumors

**Most common ovarian tumor type**

**Benign (serous cystadenoma)**:
- Thin-walled cysts
- Lined by ciliated columnar epithelium (resembles fallopian tube)
- Clear fluid

**Borderline (serous borderline tumor/atypical proliferative serous tumor)**:
- Epithelial proliferation
- Papillae, tufting, stratification
- Atypia but no stromal invasion
- Excellent prognosis

**Malignant (serous carcinoma)**:

**Classification**:
- **Low-grade**: Borderline tumor → low-grade carcinoma
  - KRAS, BRAF mutations
  - Slow growing, better prognosis
- **High-grade** (90% of serous carcinomas):
  - De novo from tubal intraepithelial carcinoma (fallopian tube)
  - **TP53 mutations** (>95%)
  - BRCA1, BRCA2 mutations (hereditary)
  - Aggressive, most common ovarian cancer subtype

**Pathology**:
- Bilateral (60%)
- Solid and cystic
- Papillae, psammoma bodies
- Invasion of stroma
- High grade: Marked nuclear atypia, high mitotic rate

**Spread**:
- **Transcoelomic**: Peritoneal seeding (most common)
- Lymphatic: Pelvic and para-aortic nodes
- Hematogenous (late)

#### Mucinous Tumors

**Benign, borderline, malignant**

**Pathology**:
- Large, multilocular cysts
- Mucin-filled
- Lined by mucin-secreting columnar epithelium (resembles GI epithelium)
- Usually unilateral

**Pseudomyxoma peritonei**:
- Rupture → mucinous ascites
- "Jelly belly"
- Usually from appendiceal primary (not ovary)

#### Endometrioid Carcinoma

- Resembles endometrial adenocarcinoma
- 15-20% of ovarian cancers
- Associated with endometriosis (10-20%)
- Associated with synchronous endometrial carcinoma (15-20%)

#### Clear Cell Carcinoma

- Clear, glycogen-rich cells
- Associated with endometriosis
- Resistant to chemotherapy
- Worse prognosis

#### Mature Cystic Teratoma (Dermoid Cyst)

**Most common germ cell tumor** (>95%)

**Pathology**:
- Benign
- Cystic mass
- Hair, sebaceous material
- **Ectodermal differentiation predominates**: Skin, hair follicles, sebaceous glands, teeth
- Can have other tissues: Cartilage, bone, thyroid (struma ovarii), neural
- **Squamous cell carcinoma** can arise (rare, 1-2%)

**Clinical**:
- Reproductive age (20-40 years)
- Often asymptomatic (incidental)
- Complications: Torsion, rupture (chemical peritonitis)

#### Dysgerminoma

**Ovarian counterpart of seminoma**

- Most common malignant germ cell tumor
- **Young women** (10-30 years)
- Sheets of uniform cells, lymphocytes
- **OCT4, PLAP, c-KIT positive**
- **Radiosensitive**
- **Excellent prognosis**

#### Granulosa Cell Tumor

**Most common sex cord-stromal tumor**

**Adult type** (95%):
- Postmenopausal women
- **Estrogen production** → endometrial hyperplasia, bleeding, carcinoma
- **Call-Exner bodies**: Rosette-like structures with eosinophilic material
- **Coffee bean nuclei**: Grooved nuclei
- **Low-grade malignant**: Late recurrences (10-20 years)

**Juvenile type** (5%):
- Children, young women
- More aggressive

#### Ovarian Carcinoma - General

**Epidemiology**:
- 5th leading cause of cancer death in women
- **"Silent killer"**: Most diagnosed at advanced stage (stage III-IV)
- Peak age: 60-65 years

**Risk factors**:
- **Nulliparity**, early menarche, late menopause (lifetime ovulations)
- Family history
- **BRCA1 mutation**: 40% lifetime risk
- **BRCA2 mutation**: 20% lifetime risk
- Lynch syndrome

**Protective factors**:
- **Oral contraceptives** (decrease ovulations)
- Pregnancy, breastfeeding
- Tubal ligation

**Clinical**:
- Often asymptomatic until advanced
- Abdominal distension, bloating
- Pelvic pain
- Ascites
- **CA-125**: Tumor marker (elevated, but not specific)

**Staging**: FIGO (surgical)
- **Stage I**: Confined to ovaries
- **Stage II**: Pelvic extension
- **Stage III**: Peritoneal implants or lymph nodes (most common at diagnosis)
- **Stage IV**: Distant metastases (pleural effusion, liver parenchyma)

**Treatment**:
- **Surgery**: Debulking (hysterectomy, BSO, omentectomy)
- **Chemotherapy**: Platinum (carboplatin or cisplatin) + taxane (paclitaxel)
- **PARP inhibitors**: BRCA-mutated tumors (olaparib, niraparib)
- **Anti-VEGF**: Bevacizumab

**Prognosis**:
- **Overall 5-year survival**: 45%
- **Stage I**: 90%
- **Stage III**: 40%
- **Stage IV**: 15%
- High-grade serous: Worst prognosis

### Breast Pathology

#### Fibrocystic Change

**Most common breast disorder**

**Not a disease, but benign changes**

**Components**:
- **Cysts**: Blue dome cysts (apocrine metaplasia)
- **Fibrosis**: Stromal fibrosis
- **Adenosis**: Increased number of acini per lobule
- **Epithelial hyperplasia**: Usual or atypical

**Clinical**:
- Breast pain, tenderness (mastalgia)
- Lumpy, nodular breast
- Cyclic changes (worse premenstrual)
- Multiple, bilateral

**No increased cancer risk** (usual hyperplasia without atypia)

**Atypical hyperplasia**: Increased risk

#### Fibroadenoma

**Most common benign breast tumor**

**Epidemiology**:
- Young women (20-35 years)
- Estrogen-dependent

**Pathology**:
- Well-circumscribed, mobile mass
- **Biphasic**: Epithelial and stromal proliferation
- Compressed ducts surrounded by stroma
- Intracanalicular (stroma compresses ducts) or pericanalicular (round ducts)

**Clinical**:
- Firm, rubbery, mobile mass ("breast mouse")
- Painless
- May enlarge during pregnancy

**Treatment**: Observation or excision

**No malignant potential** (extremely rare)

#### Breast Carcinoma

**Most common cancer in women** (excluding skin)

**Epidemiology**:
- Lifetime risk: 1 in 8 women
- 2nd leading cause of cancer death in women (after lung)
- Peak age: 60-70 years (invasive), younger for BRCA-associated

**Risk factors**:
- **Age** (most important)
- **Gender** (female >> male, 100:1)
- **Genetics**:
  - **BRCA1**: 70% lifetime risk (triple-negative subtype)
  - **BRCA2**: 60% lifetime risk (ER+ subtype)
  - TP53 (Li-Fraumeni)
  - PTEN (Cowden syndrome)
- **Reproductive**:
  - Early menarche (<12), late menopause (>55)
  - Nulliparity, first pregnancy >30
  - No breastfeeding
  - (More lifetime estrogen exposure)
- **Exogenous hormones**: HRT (estrogen + progestin), oral contraceptives (slight)
- **Previous breast cancer**
- **Atypical hyperplasia, LCIS**
- **Radiation exposure**
- **Obesity** (postmenopausal, aromatase in adipose tissue)
- **Alcohol**

**Protective**: Pregnancy (young age), breastfeeding, exercise

**Classification**:

**Non-invasive (in situ)**:
- **Ductal carcinoma in situ (DCIS)**: 20% of breast cancers
  - Confined to ducts
  - No invasion of basement membrane
  - Architectural patterns: Solid, cribriform, papillary, comedo
  - Comedo: Central necrosis, high grade, calcifications
  - Risk factor for invasive carcinoma (20-30% if untreated)
  - Treated with excision ± radiation
- **Lobular carcinoma in situ (LCIS)**: Marker of increased risk
  - Confined to lobules
  - Bilateral risk (both breasts at risk)
  - Not considered true malignancy, but marker
  - No mass, no calcifications (incidental finding)
  - 20-30% develop invasive carcinoma (either breast, usually IDC)
  - Observation or chemoprevention

**Invasive**:
- **Invasive ductal carcinoma (IDC), no special type (NST)** (75-80%)
  - Most common type
  - Firm, irregular, stellate mass
  - Desmoplastic stroma
  - Nests and cords of cells invading stroma
  - Variable differentiation (tubule formation, nuclear grade, mitoses)
  - Nottingham grade (1-3)
- **Invasive lobular carcinoma (ILC)** (10-15%)
  - Single-file linear pattern (Indian file)
  - Targetoid pattern around ducts
  - Mucin-producing (signet-ring cells)
  - **Loss of E-cadherin** (CDH1)
  - Bilateral (20%)
  - Difficult to detect (mammography, palpation)
  - ER/PR positive, HER2 negative
- **Special types** (better prognosis): Tubular, mucinous, medullary, papillary

**Molecular subtypes** (clinically relevant):

Based on **ER, PR, HER2, Ki-67**:

**Luminal A** (40%):
- ER+, PR+, HER2-, low Ki-67
- **Best prognosis**
- Endocrine therapy responsive

**Luminal B** (20%):
- ER+, PR+/-, HER2+ or HER2- with high Ki-67
- Intermediate prognosis
- Endocrine + chemotherapy ± anti-HER2

**HER2-enriched** (10-15%):
- ER-, PR-, HER2+
- Aggressive
- **Trastuzumab** (Herceptin) - anti-HER2 therapy
- Improved prognosis with targeted therapy

**Triple-negative/Basal-like** (15-20%):
- ER-, PR-, HER2-
- **Worst prognosis** (no targeted therapy)
- More common in BRCA1, African Americans, young women
- Chemotherapy only option (no endocrine or anti-HER2)
- High grade, aggressive

**Staging**: TNM system
- **T**: Tumor size
- **N**: Lymph nodes (sentinel lymph node biopsy)
- **M**: Metastases

**Metastases**: Axillary lymph nodes, bone, lung, liver, brain

**Clinical**:
- **Palpable mass** (most common)
- **Skin changes**: Dimpling, peau d'orange, nipple retraction
- **Nipple discharge** (bloody)
- **Paget disease**: Eczematous nipple (underlying DCIS/invasive)
- **Inflammatory breast cancer**: Erythema, edema, warmth (tumor emboli in dermal lymphatics)

**Screening**:
- **Mammography**: Age 40-50 (guidelines vary), annual or biennial
- MRI: High-risk women (BRCA)

**Treatment**:
- **Surgery**: Lumpectomy + radiation or mastectomy
- **Sentinel lymph node biopsy**
- **Systemic therapy**:
  - **Endocrine**: Tamoxifen (premenopausal), aromatase inhibitors (postmenopausal) - ER+ tumors
  - **Chemotherapy**: AC-T (doxorubicin, cyclophosphamide, paclitaxel)
  - **Anti-HER2**: Trastuzumab, pertuzumab - HER2+ tumors
  - **PARP inhibitors**: Olaparib - BRCA-mutated

**Prognosis**: Depends on stage, grade, molecular subtype
- **Localized**: 99% 5-year survival
- **Regional**: 86%
- **Distant**: 29%

## Key Points

### Renal Pathology
- Glomerulonephritis presents as nephrotic or nephritic syndrome
- MCD: Most common nephrotic in children, steroid-responsive
- FSGS: Most common nephrotic in African American adults, worse prognosis
- PSGN: Post-streptococcal, excellent prognosis in children
- Diabetic nephropathy: Leading cause of ESRD
- Clear cell RCC: Most common renal malignancy, VHL inactivation

### Urological Pathology
- Urothelial carcinoma: Painless hematuria, smoking major risk factor
- Muscle-invasive disease requires cystectomy

### Prostate
- BPH: Very common, transition zone, obstructive symptoms
- Prostatic adenocarcinoma: Most common cancer in men, peripheral zone, Gleason grading

### Testis
- Germ cell tumors: Most common in young men (20-35)
- Seminoma: Radiation-sensitive, excellent prognosis
- Mixed GCT most common overall
- Markers: AFP (yolk sac), hCG (choriocarcinoma)
- >95% cure rate even with metastases

### Gynecologic Pathology
- HPV causes cervical dysplasia and cancer; vaccination prevents
- Endometrial carcinoma: Type I (endometrioid, estrogen-related) vs. Type II (serous, TP53-mutated)
- Ovarian cancer: Silent killer, most diagnosed at advanced stage, poor prognosis
- High-grade serous most common subtype, TP53 mutations, BRCA-associated

### Breast
- Most common cancer in women
- Molecular subtypes guide treatment
- ER+ tumors: Endocrine therapy
- HER2+ tumors: Trastuzumab
- Triple-negative: Chemotherapy only, worst prognosis
- BRCA mutations: High lifetime risk, prophylactic surgery option

## References

1. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Elsevier; 2021. Chapter 20: The Kidney; Chapter 21: The Lower Urinary Tract and Male Genital System; Chapter 22: The Female Genital Tract; Chapter 23: The Breast.

2. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, et al. Molecular Pathology of Pancreatic Cancer. Cancer J. 2001;7(4):251-258.

3. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs. Eur Urol. 2016;70(1):93-105.

4. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. IARC; 2014.

5. WHO Classification of Tumours Editorial Board. Breast Tumours. WHO Classification of Tumours Series. 5th ed. Vol 2. IARC; 2019.

6. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70(1):106-119.

7. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2016;40(2):244-252.

8. Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs. Eur Urol. 2022;82(5):469-482.

9. American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024.

10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Ovarian Cancer, Prostate Cancer. Version 1.2024.
